Linfomas T periféricosestudio de marcadores histológicos, inmunofenotípicos y moleculares, y selección de terapia dirigida

Abstract

T-cell Lymphomas (PTCLs) are a very heterogeneous group of non-Hodgkin Lymphomas (NHLs), with a dismal prognosis and whose molecular basis are still poorly understood. The aim of this thesis is the identification of morphologic and immunophenotypic markers contributing to PTCLs diagnosis and targeted treatment. This study includes three points with the conclusions below: (1) Primary cutaneous anaplastic large cell lymphoma with IRF4-DUSP22 translocation exhibit peculiar histological features allowing the recognition of this molecular alteration and patient’s selection for targeted therapy. (2) Most PTCLs express CD30 in a heterogeneous way, with a good correlation with mRNA levels, and these patients are potential candidates for directed therapy with Brentuximab Vedotin. (3) JAK mutations are frequent in Cutaneous T-cell lymphomas (CTCLs), and can be inhibited with ruxolitinib. Specific therapies, either with monoclonal antibodies or targeted therapy, will lead to an improvement of this patients poor outcome.